Infectious Diseases – News and Features

A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease.

Biota Holdings announces that the multiple centres involved in the Phase III clinical trail on its LANI CS-8958 are ready to commence treatment.

Sanger Institute has purchased 11 additional Genome Analyzers to scale up its initiative to contribute to the 1000 Genome Project.

The initial study will evaluate the safety and combined antiviral activity of R7227 and R7128 in treatment-naive patients infected with HCV genotype 1.

Geron Corporation announced the publication of preclinical data on TAT2, a small molecule telomerase activator.

Both parties collaborate to commercialize CE marked IVD infectious disease kits based on Nanogen’s proprietary MGB technology.

The Company has presented the pre-clinical results supporting the development of PRO 206 at the annual meeting of AASLD in San Francisco.

Two domains or portions of the protein NS1 combine to form tiny tubules where double-stranded RNA is hidden from the immune system, researchers say.

The study shows that an enzyme known to play a major role in lipid production was highly elevated in human liver cells exposed to the hepatitis C virus.

Researchers at Imperial College London reveals how molecular machines inside cells swing into action to activate genes at different times in a cell’s life.